CTAD 2024 | Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, introduces the Swedish BioFINDER-2 study (NCT03174938), which explored the accuracy of plasma p-tau217 in the identification of cognitively unimpaired individuals with amyloid pathology. P-tau217 demonstrated relatively high accuracy, which has the potential to improve screening of patients for trials that aim to slow down progression or even prevent the onset of symptoms in Alzheimer’s disease. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.